ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?
Alberto Puccini(Ospedale Policlinico San Martino), Alberto F. Sobrero(Ospedale Policlinico San Martino), Stefania Sciallero(Ospedale Policlinico San Martino), Alessandro Pastorino(Ospedale Policlinico San Martino), Valentino Martelli(Ospedale Policlinico San Martino)
Cited by 12
Related Papers
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
|The Lancet. Gastroenterology & hepatology|2020|249
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
|The Oncologist|2018|144
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
|Journal for ImmunoTherapy of Cancer|2019|140
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial
|Annals of Oncology|2010|110